Design and evaluation of ophthalmic pharmaceutical products

Modern Pharmaceutics, Fourth Edition, Revised and Expanded

Volumn , Issue , 2002, Pages 626-717

  Lang, John C ^a   Roehrs, Robert E ^a   Rodeheaver, Denise P ^a   Missel, Paul J ^a   Jani, Rajni ^a   Chowhan, Masood A ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952245157     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (332)

1. The United States Pharmacopeia 24 (USP)/The National Formulary 7, U.S. Pharmacopeial Convention, Rockville, MD, 1999, pp. 2113-2114.
2. C. Mazuel and M.-C. Friteyre, U.S. Patent 4,861,760 (1989).
3. J.C. Lang, J.C. Keister, P.J.T. Missel, and D.J. Stancioff, U.S. Patent 5,403,841 (1995).
4. P.J.T. Missel, J.C. Lang, and R. Jani, U.S. Patent 5,212,162 (1993).
5. R. Bawa, G.D. Cagle, R. Hall, B. Kabra, K. Markwardt, M. Shah, and J. Teague, PCT Application, WO 99/51273.
6. A. Rozier, C. Mazuel, J. Grove, and B. Plazonnet, Int. J. Pharm., 153, 191 (1997).
7. G. Meseguer, R. Gurny, P. Buri, A. Rozier and B. Plazonnet, Int. J. Pharm., 95, 229 (1993).
8. G. Majno, The Healing Hand-Man and Wound in the Ancient World, Harvard University Press, Cambridge, MA, 1975, pp. 43-45.
9. G. Majno, The Healing Hand-Man and Wound in the Ancient World, Harvard University Press, Cambride, MA, 1975, pp. 112-114.
10. G. Majno, The Healing Hand-Man and Wound in the Ancient World, Harvard University Press, Cambridge, MA, 1975, pp. 154.
11. G. Majno, The Healing Hand-Man and Wound in the Ancient World, Harvard University Press, Cambridge, MA, 1975, pp. 216, 359.
12. G. Majno, The Healing Hand-Man and Wound in the Ancient World, Harvard University Press, Cambridge, MA, 1975, pp. 348, 377.
13. D.L. Deardorf, Remington’s Pharmaceutical Sciences, 14th ed., Mack Publishing, Easton, PA, 1970, pp. 1545-1548.
14. S. Riegleman and D.L. Sorby, Dispensing of Medication, 7th ed., Mack Publishing, Easton, PA, 1971, pp. 880-884.
15. J.C. Lang and M.M. Stiemke, Biological barriers to ocular delivery in Ocular Therapeutics and Drug Delivery, A Multidisciplinary Approach (I.K. Reddy, ed.), Technomic Publishing Company, 1996, pp. 51-132.
16. G.C.Y. Chiou, Toxicol. Methods, 2, 139 (1992).
17. S.J. Tuft and D.J. Costner, Eye, 4, 389 (1990).
18. J.W. Cheng, S.S. Matsumoto and C.B. Anger, J. Toxicol Cutaneous Ocul. Toxicol. 14, 287 (1995).
19. W.H. Havener, Ocular Pharmacology, 2nd ed., C.V. Mosby, St. Louis, MO, 1970.
20. B. Smith, Handbook of Ocular Pharmacology, Publication Sciences Group, Action, MA, 1974.
21. P. Ellis and D.L. Smith, Ocular Therapeutics and Pharmacology, 3rd ed., C.V. Mosby, St. Louis, MO, 1969.
22. J.T. Grayston, S.P. Wang, R.L. Woolridge, and P.B. Johnson, JAMA, 172, 602 (1962).
23. J.D. Bartlett and S.D. Jaanus, Clinical Ocular Pharmacology, Butterworth-Heinemann, 1995, p. 275.
24. J.L. Byers, M.G. Holland, and J.H. Allen, Am. J. Ophthalmol., 49, 267 (1960).
25. W.D. Gingrich, JAMA, 179, 602 (1962).
26. S. Mishima and D.M. Maurice, Invest. Ophthalmol., 1, 794 (1962).
27. D.M. Maurice, Invest. Ophthalmol., 6, 464 (1967).
28. S.J. Kimura, Am. J. Ophthalmol., 34, 446 (1951).
29. A. Wessing, Fluorescein Angiography of the Retina (trans. by G.K. von Noorden), C.V. Mosby, St. Louis, MO, 1969.
30. K. Koller, Arch. Ophthalmol., 13, 404 (1884).
31. Council on Drugs, New drugs and developments in therapeutics, JAMA, 183, 178 (1963).
32. M.A. Lemp, C.H. Dohlman, and F.J. Holly, Ann. Ophthalmol., 2, 258 (1970).
33. M.A. Lemp and E.S. Szymanski, Arch. Ophthalmol., 93, 134 (1975).
34. M.A. Lemp, Scientific Exhibit, American Academy of Ophthalmology and Otolaryngology, Dallas, Sept. 1975.
35. USP 24, U.S. Pharmacopeal Convention, Rockville, MD, 1999, <71>, p. 1818.
36. British Pharmacopoeia 2000, Department of Health. The Stationery Office, London, 2000, Appendix 307.
37. USP 24, U.S. Pharmacopeal Convention, Rockville, MD, 1999, <1211>, p. 2144.
38. F.N. Marzulli and M.E. Simon, Am. J. Optom., 48, 61 (1971).
39. R.B. Hackett and T.O. McDonald, Eye irritation, in Dermatoxicology, 5th ed. (F.N. Marzulli and H.L. Maibach, eds.), Hemisphere Publishing, Washington, DC, 1996, pp. 299-305, 557-566.
40. P.K. Basu, J. Toxicol, Cutan. Ocul. Toxicol., 2, 205 (1984).
41. J.S. Friedenwald, W.F. Hughes, Jr., and H. Hermann, Arch. Ophthalmol., 31, 379 (1944).
42. C. Carpenter and H. Symth, Am. J. Ophthalmol, 29, 1363 (1946).
43. L.W. Hazelton, Proc. Sci. Sect. Toilet Goods Assoc., 17, 490 (1973).
44. L.M. Carter, G. Duncan, and G.K. Rennie, Exp. Eye Res., 17, 5 (1952).
45. J.H. Kay and J.C. Calandra, J. Soc., Cosmet. Chem., 13, 281 (1962).
46. K.L. Russell and S.G. Hoch, Pro. Sci. Sect. Toilet Goods Assoc., 37, 27 (1962).
47. I. Gaunt and K.H. Harper, J. Soc. Cosmet. Shem., 15, 290 (1964).
48. S.P. Battista and E.S. McSweeney, J. Soc. Cosmet. Chem., 16, 119 (1965).
49. J.H. Becklet, Am. Perum. Cosmet, 80, 51 (1965).
50. C.T. Bonfield and R.A. Scala, Proc. Sci. Sect. Toilet Goods Assoc., 43, 34 (1965).
51. E.V. Buehler and E.A. Newmann, Toxicol. Appl. Pharmacol., 6, 701 (1964).
52. C.H. Dohlman, Invest. Ophthalmol., 10, 376 (1971).
53. M.J. Hogan and L.E. Zimmerman, in Ophthalmic Pathology: An Atlas and Textbook, 2nd ed., W.B. Saunders, Philadelphia, 1962.
54. R.R. Phister, Invest. Ophthalmol., 12, 654 (1973).
55. D.M. Maurice, The Eye, Vol. 1 (H. Davson, ed.), Academic Press, New York, 1969, pp. 489-600.
56. J.H. Prince, C.D. Diesen, I. Eglitis, and G.L. Ruskell, Anatomy and Histology of the Eye and Orbit in Domestic Animals, Charles C Thomas, Springfield, IL, 1960.
57. H. Davson, in The Eye, Vol. 1 (H. Davson, ed.), Academic Press, New York, 1969, pp. 217-218.
58. B.S. Fine and M. Yanoff, Ocular Histology: A Text and Atlas, Harper & Row, New York, 1972.
59. W.R. Green, J.B. Sullivan, R.M. Hehir, L.G. Scharpf, and A.W. Dickinson, A Systemic Comparison of Chemically Induced Eye Injury in the Albino Rabbit and Rhesus Monkey, Soap and Detergent Association, New York, 1978, pp. 405-415.
60. B.S. Fine and M. Yanoff, Ocular Histology: A Text and Atlas, Harper & Row, New York, 1972.
61. Committee for the Revision of NAS Publication 1138, National Research Council, Principles and Procedures for Evaluating the Toxicity of Household Substances, National Academy of Sciences, Washington, DC, 1977, pp. 41-56.
62. Interagency Regulatory Liaison Group, Testing Standards and Guidelines Work Group, Recommended Guidelines for Acute Eye Irritation Testing, Jan. 1981.
63. J.H. Draize, Food Drug Cosmet. Law J., 10, 722 (1955).
64. J.H. Draize and E.A. Kelley, Proc. Sci. Sect. Toilet Goods Assoc., 17, 1 (1959).
65. J.H. Draize, J. Pharmacol. Exp. Ther., 82, 377 (1944).
66. Food Drug Cosmet. Law Rep., 233, 8311; 440, 8313; 476, 8310.
67. L.H. Bruner, R.D. Parker and R.D. Bruce, Fund. Appl. Toxicol., 19, 330 (1992).
68. M. York and W. Steiling, J. Appl. Toxicol., 18, 233 (1998).
69. R.B. Nussenblatt, A. Bron, W. Chambers, J.P. McCulley, M. Pericoi, J.L. Ubels, and H.F. Edelhauser, J. Toxicol. Cut. Ocular Toxicol, 17, 103 (1998).
70. M. Balls, P.A. Botham, L.H. Bruner and H. Spielmann, Toxic. In Vitro 9, 871 (1995).
71. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical trials for Pharmaceuticals. FDA Docket No 97D-0147. Fed. Reg. 62(227), 62,922 (1997).
72. Timing of Non-Clinical Safety Studies for the Conduct of Human Clinical trials for Pharmaceuticals. Fourth International Conference on Harmonization. International Conference on Harmonization, Brussels, 1997.
73. R.B. Hackett, Lens Eye Toxic. Res. 7, 181 (1990).
74. A.W. Hayes, Principles and Methods of Toxicology, 3rd ed., Raven Press, New York, 1994.
75. Guidance for Industry: Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products. Center for Devices and Radiologic Health, FDA, Rockville, MD, 1997.
76. Biological evaluation of medical devices-Part 5: Tests for cytotoxicity: in vitro methods. ISO 10993-5:1992(E). International Standards Organization, 1992.
77. Biological evaluation of medical devices-Part 10: Tests for irritation and sensitization. ISO 10993-10:1992. International Standards Organization, 1992.
78. J.W. Shell and R.W. Baker, Ann. Ophthalmol., 7, 1637 (1975).
79. W.M. Grant, Toxicology of the Eye, Charles C Thomas, Springfield, IL, 1974, p. 259.
80. H.F. Edelhauser, D.L. Van Horn, R.W. Scholtz, and R.A. Hyndiuk, Am. J. Ophthalmol., 81, 473 (1976).
81. S.E. Herrell and D. Heilman, Am. J. Med. Sci., 206, 221 (1943).
82. USP 24, U.S. Pharmacopeial Convention, Rockville, MD, 1999, <771>, p. 1965.
83. C. Shopsis, E. Borenfreund, J. Walberg, and D.M. Stark, Alternative Methods in Toxicology, Vol. 2 (A.M. Goldberg, ed.), Mary Ann Liebert, New York, 1984, pp. 103-114.
84. E. Borenfreund and O. Borrero, Cell Biol. Toxicol., 1, 55 (1984).
85. C. Shopsis and S. Sathe, Toxicology, 29, 195 (1984).
86. R. Neville, P. Dennis, D. Sens, and R. Crouch, Curr. Eye Res., 5, 367 (1986).
87. M.E. Stern, H.F. Edelhauser, and J.W. Hiddemen, Methods of Evaluation of Corneal Epithelial and Endothelial Toxicity of Soft Contact Lens Preservatives. Presented at Contact Lens International Congress, Las Vegas, Nevada, March 1985.
88. H.F. Edelhauser, M.E. Antione, H.J. Pederson, J.W. Hiddemen, and R.G. Harris, J. Toxicol. Cutan. Ocul. Toxicol., 2(1), 7 (1983).
89. S.J. Krebs, M.E. Stern, J.W. Hiddemen, and H.F. Edelhauser, CLAO J., 10(1), 35 (1984).
90. H.E. Seifried, J. Toxicol. Cutan. Ocul. Toxicol., 5, 89 (1986).
91. D.M. Stark, C. Shopsis, E. Borenfreund, and J. Walberg, Alternative Methods of Toxicology, Vol. 1, Product Safety Evaluation, Mary Ann Liebert, New York, 1983, pp. 127-204.
92. J.M. Frazier, Dermatotoxicology, 4th ed. (F.N. Marzulli and H.L. Maibach, eds.), Hemisphere Publishing, Washington, DC, 1991.
93. N.L. Burstein, Invest. Ophthalmol. Vis. Sci., 25, 1453 (1984).
94. D. Maurice and T. Singh, A permeability test for acute corneal toxicity, Toxicol. Lett., 31, 125 (1986).
95. N.L. Burstein, Invest. Ophthalmol. Vis. Sci., 7, 308 (1980).
96. R.R. Pfister and N. Burstein, Invest. Ophthalmol. Vis. Sci., 15, 246 (1976).
97. A.M. Tonjum, Acta Ophthalmol., 53, 358 (1975).
98. H. Ichijima, W.M. Petroll, J.V. Jester, and H.D. Cavanagh, Cornea, 11, 221 (1992).
99. P.S. Imperia, H.M. Lazarus, R.E. Botti, Jr., and J.H. Lass, J. Toxicol. Cutan. Ocul. Toxicol., 5, 309 (1986).
100. H.B. Collins and B.E. Grabsch, Am. J. Optom. Physiol. Opt., 59, 215 (1982).
101. J. Ubels, J. Toxicol. Cutan. Ocul. Toxicol., 1, 133 (1982).
102. B.J. Tripathi and R.C. Tripathi, Lens Eye Toxicol. Res., 6, 395 (1987).
103. H.A. Baldwin, T.O. McDonald, and C.H. Beasley, J. Soc. Cosmet. Chem., 25, 181 (1973).
104. Fed. Reg., 18, 351 (1953).
105. C.W. Bruch, Drug Cosmet. Ind., 118(6), 51 (1976).
106. C. Teping and B. Wiedemann, Klin. Monatsbl. Augenheilkd., 205, 10 (1994).
107. M. Diestelhorst, S. Grunthal, and R. Suverkrup, Graefe’s Arch. Clin. Exp. Ophthalmol., 237, 394 (1999).
108. F. Levrat, P.J. Pisella and C. Baudouin, J. Fr. Ophtalmol., 22, 186 (1999).
109. F. Becquet, M. Goldschild, M.S. Moldovan, M. Ettaiche, P. Gastaud, and C. Baudouin, Curr. Eye Res. 17, 419 (1998).
110. M.L. Weiner and L.A. Kotkoskie, eds., Excipient Toxicity and Safety, Marcel Dekker, New York, 2000.
111. K. Green and J.M. Chapman, J. Toxicol. Cutan. Ocul. Toxicol., 5, 133 (1986).
112. C. Thode and H. Kilp, Fortschr. Ophthalmol., 79, 125 (1982).
113. K. Green, J. Chapman, L. Cheeks, and R. Clayton, Conc. Toxicol., 4, 126 (1987).
114. A.R. Gassett, Y. Ishii, H.E. Kaufman, and T. Miller, Am. J. Ophthalmol., 78, 98 (1975).
115. H. Sasaki, T. Nagano, K. Yamamura, K. Nishida, and J. Nakamura, J. Pharm. Pharmacol., 47, 703 (1995).
116. H. Sasaki, C. Tei, K. Yamamura, K. Nishida, and J. Nakamura, J. Pharm. Pharmacol., 46:871 (1994).
117. R.M.E. Richards, Aust. J. Pharm. Sci., 55, S86, S96 (1967).
118. W. Mullen, W. Shephard, and J. Labovitz, Surv. Ophthalmol., 17, 469 (1973).
119. W. Johnson, J. Am. Coll. Toxicol., 8, 589 (1989).
120. W.H. Havener, Ocular Pharmacology, C.V. Mosby, St. Louis, MO, 1966.
121. T.O. McDonald, Technical Report, Alcon Laboratories Inc., August 1975.
122. C. Baudouin, P.J. Pisella, K. Fillacier, M. Goldschild, F. Becquet, M. De Saint-Jean, and A. Bechetoille, Ophthalmology, 106, 556 (1999).
123. M. De-Saint-Jean, F. Brignole, A.F. Bringuier, A. Bauchet, G. Feldmann, and C. Baudouin, Invest. Ophthalmol. Vis. Sci., 40, 619 (1999).
124. C. Debbasch, M. De-Saint-Jean, P.J. Pisella, P. Rat, J.M. Warnet, and C. Baudouin, J. Toxicol. Cutaneous Ocul. Toxicol., 19, 79 (2000).
125. M.J. Miller, in Handbook of Disinfectants and Antiseptics, (J.M. Ascenzi, ed.), Marcel Dekker, New York, 1996, pp. 83-110.
126. P.S. Binder, D. Rasmussen, and M. Gordon, Arch. Ophthalmol., 99, 87 (1981).
127. A. Tosti and G. Tosti, Contact Dermatitis, 18, 268 (1988).
128. E. Shaw, Contact Intraocul. Lens Med. J., 6,273 (1980).
129. J. Molinari, R. Nash, and D. Badham, Int. Contact Lens Clin., 9, 323 (1982).
130. E.L. Gual, J. Invest. Dermatol., 31, 91 (1958).
131. F.A. Ellis and H.M. Robinson, Arch., Fermatol. Syphilol., 46, 425 (1941).
132. R.E. Reisman, J. Allergy, 43, 245 (1969).
133. D. Mackeen, Contact Lens J., 7, 14 (1978).
134. R.C. Meyer and L.B. Cohn, J. Pharm. Sci., 67, 1636 (1978).
135. W.R. Baily, Contact Lens Soc. Am. J., 6, 33 (1972).
136. E.M. Salonen, A. Vaheri, T. Tervo, and R. Beuerman, J. Toxicol. Cutan. Ocul. Toxicol., 10, 157 (1991).
137. B.J. Tripathi, R.C. Tripathi, and P.K. Susmitha, Lens Eye Toxicol. Res., 9, 361 (1992).
138. W.M. Grant, Toxicology of the Eye, 4th ed., Charles C Thomas, Springfield, IL, 1993, p. 365.
139. M.J. Doughty, Optom. Vis. Sci., 71, 562 (1994).
140. H. Sasaki, C. Tei, K. Yamamura, K. Nishida, and J. Nakamura, J. Pharm. Pharmacol., 46, 871 (1994).
141. D.E. Rudnick, H.F. Edelhauser, C.L. Hendrix, D.P. Rodeheaver, and R.B. Hackett, ARVO, 1997.
142. J.H. Chang, H. Ren, W.M. Petroll, H.D. Cavanagh, and J.V. Jester, Curr. Eye Res., 19, 171 (1999).
143. M.A. Chowhan, D.O. Helton, R.G. Harris, and C.L. Luthy (to Alcon Laboratories, Inc), U.S. Patent 5,037,647.
144. N.L. Burstein, Invest. Ophthalmol., 53, 358 (1975).
145. A.M. Tonjum, Acta Ophthalmol., Vis. Sci., 19, 308 (1980).
146. J.A. Dormans and J.J. Van Logten, Toxicol. Appl. Pharmacol., 62, 251 (1982).
147. A.R. Gassett and Y. Ishii, Can. J. Ophthalmol., 10, 98 (1975).
148. K. Green, V. Livingston, K. Bowman, and D.S. Hull, Arch. Ophthalmol., 19, 1273 (1980).
149. C.G. Begley, P.J. Waggoner, G.S. Hafner, T. Tokarski, R.E. Meetz, and W.H. Wheeler, Opt. Vis. Sci., 68, 189 (1991).
150. K. Green, R.E. Johnson, J.M. Chapman, E. Nelson, and L. Cheeks, Lens Eye Toxicol. Res., 6, 37 (1989).
151. A.J. Bron, P. Daubas, R. Siou-Mermet, and C. Trinquand, Eye 12, 839 (1998).
152. F. Becquet, M. Goldschild, M.S. Moldovan, M. Ettaiche, P. Gastaud, and C. Baudouin, Curr. Eye Res., 17, 419 (1998).
153. E.A. Neuwelt, ed., Implications of the Blood-Brain Barrier and Its Manipulation, Vol. 1, Basic Science Aspects, Plenum Medical Book Company, New York, 1989.
154. M.B. Segal, ed., Barriers and Fluids of the Eye and Brain, CRC Press, Cleveland, OH, 1992.
155. H.E. Kaufman, B.A. Barron, M.B. McDonald, and S.R. Waltman, eds., The Cornea, Churchill Livingstone, New York, 1988.
156. A.K. Mitra, ed., Ocular Drug Delivery Systems, Marcel Dekker, New York, 1993.
157. B.S. Fine and M. Yanoff, Ocular Histology, Harper & Row, NY, 1979.
158. J.R. Robinson, ed., Ophthalmic Drug Delivery Systems, Academy of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, DC, 1980.
159. C.W. Conroy and T.H. Maren, J. Ocul. Pharm. Ther., 15, 179 (1999).
160. C.W. Conroy and T.H. Maren, J. Ocul. Pharm. Ther., 4, 565 (1998).
161. T.W. Olsen, H.F. Edelhauser, J.I. Lim, and D.H. Geroski, Invest. Ophthal. Vis. Sci., 36, 1893 (1995).
162. T.W. Olsen, S.Y. Aaberg, D.H. Geroski, and H.F. Edelhauser, Am. J. Ophth., 125, 237 (1998).
163. D.H. Geroski and H.F. Edelhauser, Invest. Ophthal. Vis. Sci, 41, 961 (2000).
164. D.E. Rudnick, J.S. Noonan, D.H. Geroski, M. Prausnitz, and H.F. Edelhauser, Invest. Ophthal. Vis. Sci., 40, 3054 (1999).
165. J.D. Mullins and G. Hecht, Ophthalmic preparations, in Remington’s Pharmaceutical Sciences, Vol. 18 (A.R. Genaro, Ed.), Mack Publishing, Easton, PA, 1990, pp. 1581-1595.
166. R.A. Moses, Adler’s Physiology of the Eye, 5th ed., C.V. Mosby, St. Louis, MO, 1970, p. 49.
167. S.S. Chrai, M.C. Makoid, S.P. Eriksen, and J.R. Robinson, J. Pharm. Sci., 63, 333 (1974).
168. D.I. Weiss and R.D. Schaffer, Arch. Ophthalmol., 68, 727 (1962).
169. F.T. Fraunfelder and S.M. Meyer, Drug-Induced Ocular Side Effects and Drug Interactions, Lea & Febiger, Philadelphia, 1989, pp. 442-487.
170. B.C.P. Polak, Drugs used in ocular treatment, in Meyler’s Side Effects of Drugs (M.N.G. Dukes, ed.), Elsevier, New York, 1988, pp. 988-998.
171. T.F. Patton, in Ophthalmic Drug Delivery Systems (J.R. Robison, ed.), Academy of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, DC, 1980, pp. 23-54.
172. J.C. Keister, B.R. Cooper, P.J. Missel, J.C. Lang, and D.F. Hager, J. Pharm. Sci., 80, 50 (1991).
173. A. Rozier, C. Mazuel, J. Grove, and B. Plazonnet, Int. J. Pharm., 57, 163 (1989).
174. T.J. Zimmerman, M. Sharir, G.F. Nardin, and M. Fuqua, Am. J. Ophthalmol., 114, 1 (1992).
175. A. Durward, The skin and the sensory organs, in Cunningham’s Testbook of Anatomy (G.J. Romanes, ed.), Oxford University Press, London, 1964, p. 796.
176. O.A. Candia, Invest. Ophthalmol. Vis. Sci., 33, 2575 (1992).
177. A.J. Huang, S.C. Tseng, and K.R. Kenyon, Invest. Ophthalmol. Vis. Sci., 30, 684 (1989).
178. N. Narawane, Oxidative and hormonal control of horseradish peroxidase transytosis across the pigmented rabbit conjunctiva, Ph.D. thesis, University of Southern California, 1993.
179. L.E. Stevens, P.J. Missel, and J.C. Lang, Anal. Chem., 64, 715 (1992).
180. R.H. Perry and C.H. Chilton, Chemical Engineer’s Handbook, 5th ed., McGraw-Hill, New York, 1973, Sec. 4.
181. J.M. Smith, Chemical Engineering Kinetics, 3rd ed., McGraw-Hill, New York, 1981, Chap. 3.
182. C.G. Hill, An Introduction to Chemical Engineering Kinetics and Reactor Design, John Wiley & Sons, New York, 1977.
183. P. Veng-Pedersen and W.R. Gillespie, S. Pharm. Sci., 77, 39 (1988).
184. W.R. Gillespie, P. Veng-Pedersen, E.J. Antal, and J.P. Phillips, J. Pharm. Sci., 77, 48 (1988).
185. E. Hayakawa, D.-S. Chien, K. Ingagaki, A. Yamamoto, W. Wang, and V.H.L. Lee, Pharm. Res., 9, 769 (1992).
186. H.F. Edelhauser, J.R. Hoffert, and P.O. Fromm, Invest. Ophth., 4, 290 (1965).
187. D.M. Maurice and S. Mishima, Ocular Pharmackinetics (M.L. Sears, ed.), Springer-Verlag, Berlin, 1984, pp. 19-116.
188. R.D. Schoenwald and R.L. Ward, J. Pharm. Sci., 67, 786 (1978).
189. R.D. Schoenwald and H.S. Huang, J. Pharm. Sci., 72, 1266 (1983).
190. R.D. Schoenwald, Clin. Pharmacokinet, 18, 255 (1990).
191. D.-S. Chien, J.J. Homsy, C. Gluchowaski, D.D.-S. Tang-Liu, Curr. Eye Res., 9, 1051 (1990).
192. D.M. Maurice and M.V. Riley, The cornea, in Biochemistry of the Eye (C.N. Graymore, ed.), Academic Press, New York, 1970, Chap. 1.
193. E.R. Berman, Biochemistry of the Eye, Plenum Press, New York, 1991.
194. H.E.P. Bazan, private communications.
195. A. Edwards and M.R. Prausnitz, AICHE J., 44, 214 (1998).
196. A. Edwards and M.R. Prausnitz, to be published.
197. B. Alberts, D. Bray, J. Lewis, M. Raff, K. Roberts and J.D. Watson, Molecular Biology, of the Cell, Garland Publishing, Inc., New York, 1983.
198. L. Stryer, Biochemistry, W.H. Freeman and Company, 1981.
199. H. Lodish, D. Baltimore, A. Berk, S.L. Zipursky, P. Matsudaira, J. Darnell, Molecular Cell Biology, W.H. Freeman and Company, 1995.
200. G.L. Flynn, S.H. Yalkowsky, and T.J. Roseman, J. Pharm. Sci., 63, 479 (1974).
201. E.R. Cooper and G. Kasting, J. Controlled Release, 6, 23 (1987).
202. G. Hecht, R.E. Roehrs, E.R. Cooper, J.W. Hiddemen, F.F. Van Duzee, in Moder Pharmaceutics, 2nd Ed. (G.S. Banker and C.T. Rhodes, eds.), Marcel Dekker, New York, 1990, Chap. 14.
203. E.R. Cooper, Optimization of Transport and Biological Response with Epithelial Barriers in Biological and Synthetic Membranes, Alan R. Liss, New York, 1989, pp. 249-260.
204. R.W. Baker and H.K. Lonsdale, Controlled Release: Mechanisms and Rates (A.C. Tanquary and R.E. Lacy, eds.), Plenum Press, New York, 1974, pp. 15-71.
205. W. Wang, H. Sasaki, D.-S. Chien, and V.H. Lee, Curr. Eye Res., 10, 57 (1991).
206. P. Ashton, S.K. Podder, and V.H. Lee, Pharm. Res., 8, 1166(1991).
207. J. Liaw and J.R. Robinson, Ocular penetration enchancers, in Ocular Drug Delivery Systems (A.K. Mitra, ed.), Marcel Dekker, 1993, pp. 369-381.
208. Y. Rojanaskul, J. Liaw, and J.R. Robinson, Int. J. Pharm., 66, 133 (1990).
209. K.-I. Hosoya, Y. Horibe, K.-J. Kim, and V.H.L. Lee, J. Pharm. Exp. Therap., 285, 223 (1998).
210. K.-I. Hosoya, Y. Horibe, K.-S. Kim, and V.H.L. Lee, Inv. Ophth. Vis. Sci., 39, 372 (1998).
211. P. Saha, J.J. Yang, and V.H.L. Lee, Inv. Ophth. Vis. Sci., 39, 1221 (1998).
212. K.-I. Hosoya, Y. Horibe, K.-J. Kim, and V.H.L. Lee, Inv. Ophth. Vis. Sci., 39, 1436 (1998).
213. S.K. Basu, I.S. Haworth, M.B. Bolger, and V.H.L. Lee, Inv. Ophth. Vis. Sci., 39, 2365 (1998).
214. H. Ueda, Y. Horibe, K.-J. Kim, and V.H.L. Lee, Inv. Ophth. Vis. Sci., 41, 870 (2000).
215. D.M. Maurice, Symposium on Ocular Therapy, Vol. 9, John Wiley & Sons, New York, 1976.
216. I.H. Leopold and H.G. Scheie, Arch. Ophthalmol., 29, 811 (1943).
217. Physician’s Desk Reference for Ophthalmology, 28th Ed., 2000, Section 9.
218. D.F. Martin, F.L. Ferris, D.J. Parks, R.C. Walton, S.D. Mellow, D. Gibbs, N.A. Remaley, P. Ashton, M.D. Davis, C.C. Chan, and R.B. Nussenblatt, Arch. Ophthalmol., 115, 1389 (1997).
219. M.P. Hatton, J.S. Duker, E. Reichel, M.G. Morley and C.A. Puliafito, Retina, 18, 50 (1998).
220. B. Dhillon, A. Kamal, and C. Leen, Int. J. STD AIDS, 9, 227 (1998).
221. D.M. Maurice, private communication.
222. T.J. Smith, P.A. Pearson, D.L. Blandford, J.D. Brown, K.A. Goins, J.L. Hollins, E.T. Schmeisser, P. Glavinos, L.B. Baldwin, and P. Ashton, Arch. Ophthalmol., 110,255(1992).
223. G.E. Sanborn, R. Anand, R.E. Torti, S.D. Nightingale, S.X. Cal, B. Yates, P. Ashton, and T. Smith, Arch. Ophthalmol., 110, 188 (1992).
224. J. Xu, J. Heys, V.H. Barocas, and T.W. Randolph, Pharm. Res., 17, 664 (2000).
225. S.S. Hayreh, Exp. Eye Res., 5, 123 (1966).
226. M. Maurice, Am. J. Physiol., 252, F104 (1987).
227. S. Johnson and D.M. Maurice, Exp. Eye Res., 39, 791 (1984).
228. M. Araie and D.M. Maurice, Exp. Eye Res., 52, 27 (1991).
229. A.G. Palestine and R.F. Brubaker, Invest. Ophthalmol. Vis. Sci., 21, 544 (1981).
230. H. Lund-Andersen, B. Krogasaa, M. La Cour, and J. Larsen, Invest. Ophthalmol. Vis. Sci., 26, 698 (1985).
231. A. Hosaka, Acta Ophtallmol. Suppl., 185, 95 (1988).
232. A. Yoshida, S. Ishiko, and M. Kojima, Graefe’s Arch. Clin. Exp. Ophthalmol., 230, 78 (1992).
233. K.J. Tojo and A. Ohtori, Proceed. Int. Symp. Control. Rel. Bioact. Mater., 20, 45 (1993).
234. A. Ohtori and K. Tojo, Biol. Pharm. Bull., 17, 283 (1994).
235. K. Tojo and A. Ohtori, Math. Biosci., 123, 59 (1994).
236. K. Uno, K. Nakagawa, A. Ohtori, and K. Tojo, Drug Deliv. Systems (Jpn), 11, 133 (1998).
237. K. Tojo and A. Ohtori, Eur. J. Pharm. Biopharm., 47, 99 (1999).
238. P.M. Pinsky, D.M. Maurice and D.V. Datye, Invest. Ophthalmol. Vis. Sci. Suppl., 37, S700 (1996).
239. S. Friedrich, Y.L. Cheng, and B. Saville, Ann. Biomed. Eng., 25, 303 (1997).
240. S. Friedrich, Y.L. Cheng, and B. Saville, Curr. Eye Res., 16, 663 (1997).
241. S. Friedrich, B. Saville, and Y.L. Cheng, J. Ocular Pharm. Ther., 13, 445 (1997).
242. S. Friedrich, thesis, University of Toronto, Department of Chemical Engineering and Applied Chemistry, 1996.
243. P.J. Missel, Ann. Biomed. Eng., 28, 1307 (2000).
244. Y. Zhou and X.Y. Wu, J. Controlled Rel., 49, 277 (1997).
245. X.Y. Wu and Y. Zhou, J. Controlled Rel., 51, 57 (1998).
246. K. Tojo, Y. Morita, and A. Ohtori, Proceed. Int. Symp. Control. Rel. Bioact. Mater., 18, 293 (1991).
247. K. Uno, A. Ohtori, and K. Tojo, Atarashii Ganka (J. Eye, Japan) 11, 607 (1994).
248. Code of Federal Regulations, 21, § 210-211.
249. Clean Room and Work Station Requirements, Controlled Environment, Sec. 1-5 Federal Standard 209, Office of Technical Services, U.S. Department of Commerce, Washington, DC, Dec. 16, 1963.
250. P.R. Austin and S.W. Timmerman, Design and Operation of Clean Rooms, Business News Publishers, Detroit, MI, 1965.
251. P.R. Austin, Clean Rooms of the World. Ann Arbor Science Publishers, Ann Arbor, MI, 1967.
252. K.R. Goddard, Air filtration of microbial particles, Publication 953, U.S. Public Health Service, Washington, DC, 1967.
253. K.R. Goddard, Bull. Parente, Drug Assoc., 23, 699 (1969).
254. U.S. Patent 6,071,904, issued June 6, 2000 to Alcon Laboratories, Inc.
255. D. Jones, PDA J., 49(5), 226 (1995).
256. J.R. Sharp, Pharm. J., 239, 106 (1987).
257. J.R. Sharp, Manufact. Chem., Feb., 22, 55 (1988).
258. F. Leo, Blow/Fill/Seal Aseptic Packaging Technology in Aseptic Pharmaceutical Technology for the 1990‘s, Interpharm Press, Prairie View, IL. 1989, pp. 195-218.
259. J.R. Sharp, J. Parenter. Sci. Technol., 44(5) (1990).
260. A. Bradely, S.P. Probert, C.S. Sinclaire, and A. Tallentire, J. Parenter. Sci. Technol., 45(4), 187.
261. The Rules Governing Medicinal Products in the European Union, Vol. 4, Good Manufacturing Practices-Medicinal Products for Human and Vetrinary Use, Annex I Manufacture of Sterile Medicinal Products, Commission Directive 91/356/EEC of 13 June 1991.
262. USP 24, U.S. Pharcacopeial Convention, Rockville, MD, 1999, pp. 1752-1753.
263. Fed. Reg., 41, 106, June 1, 1976.
264. T.L. Grimes, D.E. Fonner, J.C. Griffin, and L.R. Rathburn, Bull. Parenter. Drug Assoc., 29, 64 (1975).
265. E-3A Accepted Practices for Permanently Installed Sanitary Product Pipeline and Cleaning Systems, Serial E-60500, U.S. Public Health Service, Washington, DC.
266. D.E. Cadwallader, Am. J. Hosp. Pharm., 24, 33 (1967).
267. F.G. Kronfeld and J.E. McDonald, J. Am. Pharm. Assoc. (Sci. Ed.), 42, 333 (1951).
268. S. Riegelman and D.G. Vaughn, J. Am. Pharm. Assoc. (Pract. Pharm. Ed.), 19, 474 (1958).
269. S.M. Blaugh and A.T. Canada, Am. J. Hosp. Pharm., 22, 662 (1965).
270. M.L. Linn and L.T. Jones, Am. J. Ophthalmol., 65, 76 (1968).
271. S.S. Chrai and J.R. Robinson, J. Pharm. Sci., 63, 1218 (1974).
272. C.A. Adler, D.M. Maurice, and M.E. Patterson, Exp. Eye Res., 11, 34(1971).
273. R. Castroviejo, Arch. Ophthalmol, 74, 143 (1965).
274. C. Hanna, F.T. Fraunfelder, M. Cable, and R.E. Hardberger, Am. J. Ophthalmol., 76, 193 (1973).
275. F.T. Fraunfelder, C. Hanna, M. Cable, and R.E. Hardberger, Am. J. Ophthalmol., 76, 475 (1973).
276. R. Mouly, Ann. Chir. Plast., 17, 61 (1972).
277. D.W. Newton, C.H. Becker, and G. Torosian, J. Pharm. Sci., 62, 1538 (1973).
278. R.L. Schoenwald, R.L. Ward, L.M. DeSantis, and R.E. Roehrs, J. Pharm. Sci., 67, 1280 (1978).
279. W.F. March, R.M. Stewart, A.I. Mandell, and L. Bruce, Arch. Ophthalmol., 100, 1270 (1982).
280. H.M. Liebowitz, R.K. Chang, and A.I. Mandell, Ophthalmology, 91, 1199 (1984).
281. F.W. Bowman, E.W. Knoll, M. White, and P. Mislivic, J. Pharm. Sci., 61, 532 (1972).
282. T.W. Schwartz, Am. Perum. Cosmet., 86, 39 (1971).
283. A. Zaffaroni, Proc. 31st International Congress on Pharmaceutical Science, Washington, DC, 1971.
284. J.W. Shell and R.W. Baker, Ann. Ophthalmol., 7, 1037 (1975).
285. S. Lerman and B. Reininger, Can. J. Ophthalmol., 6, 14(1971).
286. Y.F. Maichuk, Invest. Ophthalmol., 14, 87 (1975).
287. S.P. Loucas and H.M. Haddad, J. Pharm. Sci., 61, 985 (1972).
288. J. Hiller and R.W. Baker, (to Alza Corporation), U.S. Patent 3,811,444(1974).
289. A. Michaels (to Alza Corporation), U.S. Patent 3,867,519 (1975).
290. N. Keller, A.M. Longwell, and S.A. Biros, Arch. Ophthalmol., 94, 644 (1976).
291. H.F. Edelhauser, Arch. Ophthalmol., 93, 649 (1975).
292. W.H. Havener, Ocular Pharmacology, 2nd ed., C.V. Mosby, St. Louis, MO, 1970, p. 27.
293. J.W. Shell and R.W. Baker, Ann. Ophthalmol., 7, 1637 (1975).
294. W.M. Grant, Toxicology of the Eye, Charles C Thomas, Springfield, IL, 1974, p. 259.
295. B.E. McCarey, H.F. Edelhauser, and D.L. Van Horn, Invest. Ophthalmol., 12, 410 (1973).
296. D.L. Merrill, T.C. Fleming, and L.J. Girard, Am. J. Ophthalmol., 49, 895 (1960).
297. L.J. Girard, Proceedings International Congress on Ophthalmology, Brussels, Sept. 1958.
298. H.F. Edelhauser, D.L. Van Horn, R.W. Scholtz, and R.A. Hyndiuk, Am. J. Ophthalmol., 81, 473 (1976).
299. S.E. Herrell and D. Heilman, Am. J. Med. Sci., 206, 221 (1943).
300. N.S. Jaffee, Bull. Parenter. Drug Assoc., 24,218 (1970).
301. N.J. Baily, Contact Lens Spectrum, 2(7), 6 (1987).
302. K.J. Randeri, R.P. Quintana, and M.A. Chowhan, Lens care products, in Encyclopedia of Pharmaceutical Technology, Vol. 8 (J. Swarbrick and J.C. Boylan, eds.), Marcel Dekker, New York, 1993, pp. 361-402.
303. J. Tan, L. Keay, and D. Sweeney, Contact Lens Spectrum, July, 42 (2000).
304. P.R. Kastl, M.J. Refojo, and O.H. Dabezies, Jr., Review of polymerization for the contact lens fitter, in Contact Lenses: The CLAO Guide to Basic Science and Clinical Practice, 2nd ed., Vol. 1 (O.H. Dabezies, Jr., ed.), Little, Brown & Co., Boston, 1989, pp. 6.21-6.24.
305. K.A. Polse and R.B. Mandell, Arch. Ophthalmol., 84, 505 (1970).
306. P.S. Binder, Ophthalmology, 86, 1093 (1978).
307. I. Fatt and R.M. Hill, Am. J. Optom. Arch. Am. Acad. Optom., 47, 50 (1970).
308. I. Fatt, Contacto, 23(1), 6 (1978).
309. Food and Drug Administration, Guidance Document for Class III Contact Lenses, U.S. Food and Drug Administration, Silver Springs, MD, 1989.
310. N.J. Van Haeringen, Surv. Opthalmol., 26(2), 84 (1981).
311. E.J. Castillo, J.L. Koenintg, and J.M. Anderson, Biomaterials, 7, 89 (1986).
312. M. Ruben, Br. J. Ophthalmol., 59, 141 (1975).
313. D.E. Hart, Int. Contact Lens Clin., 11, 358 (1984).
314. C.G. Begley and P.J. Waggoner, J. Am. Optom. Assoc., 62, 208 (1991).
315. R.C. Tripathi, B.J. Tripathi, and C.B. Millard, CLAO J., 14, 23 (1988).
316. M.J. Miller, L.A., Wilson, and D.G. Ahrean, J. Clin. Microbiol., 16, 513 (1988).
317. M. Chowhan, T. Bilbault, R.P. Quintana, and R.A. Rosenthal, Contactologia, 15, 190 (1993).
318. R. Jacob, Int. Contact Lens Clin., 15, 317 (1988).
319. D. Holsky, J. Am. Optom. Assoc., 55, 205 (1993).
320. M.M. Hom and M. Pickford, Int. Eyecare, 2, 325 (1986).
321. R.L. Davis, Int. Contact Lens Clin., 10, 277 (1983).
322. M.A. Chowhan, R.P. Quintana, B.S. Hong, T. Bilbault, and R.A. Rosenthal (to Alcon Laboratories, Inc.) U.S. Patent 5,948,738.
323. C.G. Begley, S. Paraguia, and C. Sporm, J. Am. Optom. Assoc., 61, 190 (1990).
324. N. Tarrantino, R.C. Courtney, L.A. Lesswell, D. Keno, and I. Frank, Int. Contact Lens Clin., 15, 25 (1988).
325. R.D. Houlsby, M. Ghajar, and G. Chavez, J. Am. Optom. Assoc., 59, 184 (1988).
326. C.B. Anger, K. Ambrus, J. Stocker, S. Kapadia, and L. Thomas, Spectrum, 9, 46 (1990).
327. M. Chowhan, T. Bilbault, R.P. Quintana (to Alcon Laboratories, Inc.), U.S. Patent 5,370,744.
328. M. Chowhan, D. Keith, H. Chen, R. Stone, Poster at Annual Meeting, CLAO, Las Vegas, 1998.
329. Food and Drug Administration, Draft Testing Guidelines for Class III Soft (Hydrophilic) Contact Lens Solutions, U.S. Food and Drug Administration, Silver Springs, MD, 1985.
330. N.A. Brennan and N. Efron, Optom. Vis. Sci., 66, 834 (1989).
331. N. Efron, T.R. Goldwig, and N.A. Brennan, CLAO J., 17, 114(1991).
332. M. Chowhan, H. Chen, R. Stone, R.A. Rosenthal, D. Keith, and J. Stein, Alcon Laboratories, Inc., Technical Report.